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arrhythmia. Despite guidelines for testing from regulatory agencies, these interactions are usually discovered after drugs
are marketed and may go undiscovered for years.
OBJECTIVES Using a combination of adverse event reports, electronic health records (EHR), and laboratory experi-
ments, the goal of this study was to develop a data-driven pipeline for discovering QT-DDIs.
METHODS 1.8 million adverse event reports were mined for signals indicating a QT-DDI. Using 1.6 million electro-
cardiogram results from 380,000 patients in our institutional EHR, these putative interactions were either refuted or
corroborated. In the laboratory, we used patch-clamp electrophysiology to measure the human ether-à-go-go-related
gene (hERG) channel block (the primary mechanism by which drugs prolong the QT interval) to evaluate our top
candidate.
RESULTS Both direct and indirect signals in the adverse event reports provided evidence that the combination of ceftri-
axone (a cephalosporin antibiotic) and lansoprazole (a proton-pump inhibitor) will prolong the QT interval. In the EHR, we
found that patients taking both ceftriaxone and lansoprazole had signiﬁcantly longer QTc intervals (up to 12ms inwhitemen)
and were 1.4 times more likely to have a QTc interval above 500 ms. In the laboratory, we found that, in combination and at
clinically relevant concentrations, these drugs blocked the hERG channel. As a negative control, we evaluated the combi-
nation of lansoprazole and cefuroxime (another cephalosporin), which lacked evidence of an interaction in the adverse event
reports. We found no signiﬁcant effect of this pair in either the EHR or in the electrophysiology experiments. Class effect
analyses suggested this interactionwas speciﬁc to lansoprazole combinedwith ceftriaxone but notwith other cephalosporins.
CONCLUSIONS Coupling data mining and laboratory experiments is an efﬁcient method for identifying QT-DDIs.
Combination therapy of ceftriaxone and lansoprazole is associated with increased risk of acquired long QT syndrome.
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ABBR EV I A T I ON S
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APD70 = action potential
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hERG = human ether-à-go-go-
related gene
LQTS = long QT syndrome
PPI = proton-pump inhibitor
QT-DDI = QT interval-
prolonging drug-drug
interaction
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1757administered individually. Nonantiarrhythmic com-
pounds that increase the QT/QTc interval by 20 ms
or more are unlikely to be approved, and a compound
associated with an increase of 10 ms or more would
face many challenges (3). Even a 5 ms increase would
prompt an evaluation of the risks and beneﬁts of the
new compound (3). Studies of both cardiac and
noncardiac compounds found that a QTc interval
above 500 ms is associated with signiﬁcant risk of
Torsades de pointes (4,5).
Acquired LQTS is of particular concern when it is
not anticipated and occurs as the result of a QT
interval-prolonging drug-drug interaction (QT-DDI)
(2,6). QT-DDIs are not routinely evaluated pre-
clinically and can go undiscovered for years. For
example, quetiapine (an antipsychotic agent) was
on the market for nearly 10 years before reports
of a QT-DDI with methadone (an analgesic agent)
prompted investigation into a possible mechanism
(7). It took 3 more years before a label change was
made to caution against the use of quetiapine in
combination with other drugs known to prolong the
QT interval.SEE PAGE 1765Large clinical databases, such as electronic health
records (EHR), represent an opportunity to rapidly
detect QT-DDIs and save lives (8,9). Drug safety al-
gorithms could be applied to health record data in
near real time, ﬂagging potentially dangerous drug
interactions before they become widespread. Fur-
thermore, these analyses are in situ and therefore
focus on the most important drug combinations:
those that are actually used in clinical practice. Un-
fortunately, analysis of medical records is complex,
due to issues of missing data, noise, and bias (10). This
leads to high false positive rates and algorithms that
often will mislead health care providers. Laboratory
experiments, especially if they are high-throughput,
can be used to screen data-mined hypotheses for
plausibility. Following observational analysis with
conﬁrmatory prospective experiments can remove
the spurious signals, enabling clinically useful dis-
coveries (11).
We developed a data science pipeline to mine
potential QT-DDIs from clinical databases. In this
pipeline, we combine evidence of QT-DDIs from the
FDA Adverse Event Reporting System (FAERS) and
the EHR at New York-Presbyterian/Columbia Uni-
versity Medical Center (CUMC-EHR). We identiﬁed a
putative interaction between lansoprazole (a
proton-pump inhibitor [PPI]) and ceftriaxone (a
cephalosporin antibiotic). Importantly, this is an
interaction that would not have been suspectedusing current surveillance methods. We
used patch-clamp electrophysiology of cells
stably expressing human ether-à-go-go-
related gene (hERG) channels to establish a
physiological mechanism. We further con-
ﬁrmed the speciﬁcity of our pipeline by also
investigating the combination of cefurox-
ime (another cephalosporin) and lansopra-
zole, a drug pair that did not have evidence
of an interaction in FAERS. In the clinic,
patients on the combination of ceftriaxone
and lansoprazole had 12 ms (95% conﬁ-
dence interval [CI]: 7 to 15 ms) longer QTc
intervals than patients exposed to either
drug alone and were 1.4 times as likely to
have a QTc interval above 500 ms. The
negative control showed no signiﬁcant ef-
fect. A QT-DDI between ceftriaxone and
lansoprazole has the potential for signiﬁcant
morbidity and mortality.
METHODS
DATA SOURCES. We used 2 independent databases
to investigate possible QT-DDIs. The ﬁrst database
(TWOSIDES) was a derivative of 1.8 million adverse
event reports from FAERS mined for evidence of
adverse drug-drug interactions that could not be
explained by the individual effects of the drugs (12).
The second database consisted of 1.6 million elec-
trocardiograms (ECGs) from 382,221 patients treated
at New York-Presbyterian/CUMC between 1996 and
2014. To obtain the heart rate-corrected QT (QTc) in-
tervals, we wrote a parser to automatically extract
the patient identiﬁer, laboratory date, and QTc value
from the ECG reports. QTc values were calculated
using Bazett’s formula. We manually checked 50
abnormal ECGs (deﬁned as QTc >500 ms) to conﬁrm
we were extracting the correct values and found that
the parser obtained 100% precision and recall. We
implemented the pipeline using Python 2.7.9 (Python
Foundation, Wilmington, Delaware) and R version
3.2.2. (R Foundation for Statistical Computing,
Vienna, Austria).
IDENTIFICATION OF CANDIDATE QT-DDIs. We used
the side effect reporting frequencies in TWOSIDES to
ﬁnd drug pairs signiﬁcantly over-reported with the 6
adverse events in the standardized MedDRA (Medical
Dictionary for Regulatory Activities) query for
“Torsade de Pointes/QT prolongation”; we call this
the direct evidence model (12). However, most drug
pairs are not directly reported with QT prolongation.
In addition, we performed latent signal detection, a
method we have previously validated (13,14), to
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1758identify candidate QT-DDIs that lacked prior direct
evidence. To perform latent signal detection, we
used machine learning to deﬁne and validate a side
effect proﬁle of 13 side effects associated with
known QT-prolonging compounds. Some of these
latently identiﬁed side effects (such as arrhythmia
and rhabdomyolysis) are positively correlated with
QT interval prolongation, whereas others (such as
hemorrhage and myocardial infarction) are nega-
tively correlated (Figure 1B). We previously validated
the method using drug pairs containing a known
QT-prolonging drug (2) and demonstrated high
speciﬁcity and sensitivity (Online Figure 1). We then
scanned for novel drug interactions in the TWOSIDES
database that matched the side effect proﬁle; we
refer to this as indirect evidence. We scored each
drug pair for the amount of both direct and indirect
evidence.
EVALUATION OF CANDIDATE QT-DDIs USING THE EHR.
We attempted to corroborate (or refute) each of the
candidate QT-DDI hypotheses using the heart rate-
corrected QTc values from ECGs stored in the
CUMC-EHR. For each candidate drug-drug interac-
tion, we deﬁned an exposed cohort and 2 control
cohorts. Those patients included in the exposed
cohort were administered both of the drugs within a
7-day window. Those in the control cohorts had evi-
dence of exposure to only 1 of the 2 drugs ever in their
records. Only patients who had at least 1 ECG in the
following 36 days after drug exposure (either combi-
nation or single) were included. Corroboration
required that we found signiﬁcantly longer heart rate-
corrected QTc intervals in patients on combination
treatment compared with patients on either drug
alone. The CUMC-EHR uses Bazett’s formula by
default; we also evaluated the change in QT interval
using the Fridericia, Framingham, and Hodges
correction formulae (15). Because the distributions of
QTc intervals were non-normal, we assessed signiﬁ-
cance using a Mann-Whitney U test with a Bonferroni
correction for multiple hypothesis testing. We further
veriﬁed that this effect could not be explained by
concomitant medications (analysis of covariance with
concomitant medications modeled as categorical
variables) (14). This analysis was stratiﬁed by sex
because QT interval durations are known to differ
between men and women (16). We evaluated the ef-
fects of each drug pair both on individual races and
on all races combined (Mann-Whitney U test). We also
performed a post hoc power analysis to estimate our
ability to detect a change in QTc interval for the
sample and effect sizes present in our EHR (17).
Only those QT-DDIs corroborated by the EHR data(in either men, women, or both) were considered for
laboratory analysis.
PATCH-CLAMP ELECTROPHYSIOLOGY. QT-prolong-
ing drugs have in common the ability to block the
hERG channel (which conducts IKr) in the heart. We
evaluated the combination of ceftriaxone and lanso-
prazole by performing patch-clamp electrophysiology
of cells stably expressing IKr. Using an automated
patch-clamp system (PatchLiner, Nanion, Germany)
in voltage clamp mode, we examined the
concentration-dependent block of the IKr current
by each drug individually, as well as in combina-
tion, using dimethyl sulfoxide as vehicle control
(Figure 1D). We applied a voltage protocol with a step
to þ40 mV, followed by a return to 40 mV, to elicit
the inward-rectifying tail current. This protocol was
repeated every 20 s for the length of the experiment,
and after 10 consecutive sweeps in each concentra-
tion, the concentration was increased. We then
averaged the current at the end of each drug appli-
cation and normalized it to the control to measure the
block by each compound. We assessed signiﬁcance by
using a test of repeated measures on the log-
normalized block percentages.
We performed patch-clamp electrophysiology ex-
periments as described for ceftriaxone alone, lanso-
prazole alone, and ceftriaxone and lansoprazole
combined, and similarly for the negative controls of
cefuroxime alone and cefuroxime and lansoprazole
combined. We evaluated the ability of ceftriaxone or
cefuroxime to block the hERG channel at concen-
trations of 0.1, 1, 10, 50, and 100 mM. For lans-
oprazole, we evaluated at 0.1, 1, and 10 mM. We
performed 3 combination experiments. For the
combination of ceftriaxone and lansoprazole, we
held lansoprazole constant at either 1 mM or 10 mM
and increased the dose of ceftriaxone stepwise from
0.1 to 100 mM. To evaluate our negative control of
cefuroxime and lansoprazole, we held lansoprazole
constant at 1 mM and increased the dose of cefurox-
ime stepwise from 0.1 to 100 mM. The concentrations
tested were chosen to include the range of plasma
concentrations usually reached during routine clin-
ical use of the drugs (1.9 to 3.9 mM for lansoprazole,
24 to 228 mM for ceftriaxone, and 35 to 428 mM for
cefuroxime) (18–21).
COMPUTATIONAL MECHANISTIC MODEL. We used a
computational model of the human ventricular myo-
cyte (22) to simulate the action potential for the hERG
block we observed for ceftriaxone, lansoprazole, and
the combination from our laboratory experiments.
We ran the model for a ventricular action potential
paced at 1 Hz with baseline conditions and 10% or 55%
FIGURE 1 Data Science and Experimental Pipeline for Identifying and Validating QT-DDIs
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(A) Chemical structures for ceftriaxone (cephalosporin) and lansoprazole (proton pump inhibitor), which we predicted would have a QT-DDI. We predicted cefuroxime
(cephalosporin) and lansoprazole not to interact. (B) QT-DDI discovery in FAERS: data-driven side effect proﬁle containing latent evidence of a QT-DDI (solid boxes ¼
positive correlation with QT prolongation; open boxes ¼ negative correlation). Each bar represents the reporting frequency of a given side effect in FAERS for ceftriaxone
(green), lansoprazole (blue), cefuroxime (orange), ceftriaxone þ lansoprazole (red), and cefuroxime þ lansoprazole (purple). (C) Retrospective corroboration in
electronic health records. (Left) Differences in QTc interval (mean  95% CI) between cases (patients prescribed the drug pair) and controls (patients on only 1 drug).
We stratiﬁed the analysis by sex (men ¼ gray; women ¼ teal) and evaluated all races combined, as well as whites, blacks, and “other, including Hispanic” separately.
The asterisk indicates the change in QTc intervals is statistically signiﬁcant (Mann-Whitney U test with Bonferroni correction). We obtained 95% CIs by bootstrapping
case and control QTc distributions and calculating the change in median QTc for each iteration. (Right) Percentage of patients with a QTc interval$500 ms (mean  95%
CI), stratiﬁed by sex and race. The asterisk indicates the combination had a signiﬁcantly greater proportion of patients with a QTc interval $500 ms than either
drug alone (independent samples Student t-test with Bonferroni correction, comparing means of single drug and combination therapy percentage$500 distributions
generated using bootstrapping). (D) Experimental validation using patch-clamp electrophysiology. (Left) Change in hERG current from control (mean  SD) for
increasing concentrations of cephalosporin alone (dashed line), and increasing concentrations of cephalosporin in the presence of a single concentration of lansoprazole
(solid lines). (Right) Representative traces from each patch-clamp electrophysiology experiment. (Top to bottom) hERG channel current in the presence of vehicle
only (control), and then cephalosporin at 3 concentrations (0.1, 10, and 100 mM); hERG channel current in the presence of lansoprazole alone and then in combination
with progressively increasing concentrations of cephalosporin. CI ¼ conﬁdence interval; other abbreviations as in Central Illustration.
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TABLE 1 Demographic and Clinical Characteristics of Cohort
Men Women
Combination of ceftriaxone þ lansoprazole
n 934 1,414
Demographic
Age, yrs 61.3  16.9 66.5  18.5
% Race distribution
White 57.3 52.9
African American 18.9 20.2
Other/unknown 23.8 26.9
QTc, ms 458 (398–588) 457 (401–571.7)
% Patients with QTc $500 ms 19.27 16.34
Combination of cefuroxime þ lansoprazole
n 107 228
Demographic
Age, yrs 66.1  15.7 67.6  17.9
% Race
White 56.1 60.1
African American 13.1 14.9
Other/unknown 30.8 25.0
QTc, ms 450 (393.6–579.4) 443.5 (398.7–579.2)
% Patients with QTc $500 ms 14.95 11.40
Ceftriaxone only
n 5,734 6,850
Demographic
Age, yrs 59.5  17.9 63.7  19.8
% Race
White 46.6 45.1
African American 19.0 18.4
Other/unknown 34.4 36.5
QTc, ms 446 (394–566) 448 (398–560)
% Patients with QTc $500 ms 14.21 11.43
Cefuroxime only
n 636 957
Demographic
Age, yrs 61.5  17.6 66.0  19.3
% Race
White 54.1 50.3
African American 20.6 19.3
Other/unknown 25.3 30.4
QTc, ms 435 (391.9–552.1) 439 (397–551.1)
% Patients with QTc $500 ms 11.16 9.09
Lansoprazole only
n 12,271 13,074
Demographic
Age, yrs 60.0  15.8 63.1  17.7
% Race
White 60.8 54.6
African American 13.9 16.7
Other/unknown 25.3 28.7
QTc, ms 443 (395–572) 445 (399–569)
% Patients with QTc $500 ms 12.84 12.07
Values are n, mean  SD, or median (95% conﬁdence interval).
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1760block of hERG current (chosen using the current block
observed in the electrophysiology experiments). We
evaluated the action potential duration at 70% of
repolarization (APD70).RESULTS
CANDIDATE QT-DDI DISCOVERY VIA DATA SCIENCE. We
detected 889 putative signals in FAERS, of which 34
(1.42 more than expected by chance, p ¼ 0.003)
were corroborated by the CUMC-EHR, after multi-
plicity correction. Twenty-six signals were eliminated
by confounder analysis for concomitant medications.
The remaining 8 combinations could not be explained
by concomitant medications and were not previously
associated with acquired LQTS (14). We prioritized
the combination of ceftriaxone and lansoprazole for
experimental validation, as lansoprazole is available
over the counter and is one of the top 200 most-
prescribed drugs (totaling over 2.6 million pre-
scriptions in 2010) (23). An interaction with a PPI
could therefore have a profound impact on patient
safety. As a negative control, we chose to evaluate the
combination of cefuroxime and lansoprazole as,
according to our algorithm, it did not match the side-
effect proﬁle for QT prolongation in FAERS (Figures 1A
and 1B).
CO-MEDICATIONOFCEFTRIAXONEANDLANSOPRAZOLE
IS ASSOCIATEDWITH PROLONGED QT IN THE EHR. Over-
all, the QTc intervals (Bazett’s correction) for male
patients taking this combination were 12 ms (95% CI:
7 to 15 ms; n ¼ 934) longer than those of patients
taking either drug alone (p < 0.001); for female pa-
tients, QTc intervals for patients taking the combi-
nation were 9 ms (95% CI: 5.2 to 11.3 ms; n ¼ 1,414)
longer than those of patients taking either drug alone
(p < 0.001) (Figure 1C). We evaluated QT interval
prolongation post hoc using the Fridericia, Fra-
mingham, and Hodges correction formulae. In men,
all 3 formulae were signiﬁcant, with p < 0.01 (Online
Table 1), and in women, Fridericia and Hodges
formulae were signiﬁcant, with p < 0.01. When
stratifying by race in addition to sex, we observed
the largest effects were in white men (12 ms increase;
95% CI: 6.5 to 17 ms; p < 0.001) and in black women
(12 ms increase; 95% CI: 3.7 to 18.5 ms; p < 0.001).
We performed a regression analysis which conﬁrmed
the increased sensitivity to the drug pair in white
patients (p ¼ 0.049) (Online Table 2). In 19% of men
taking the combination, the QTc was $500 ms, an
accepted threshold for clinical concern (3), compared
with 14% (p < 0.001) of patients taking only 1 drug
(Table 1).
Applying the same case-control analysis to cefur-
oxime and lansoprazole showed no signiﬁcant dif-
ferences in QTc intervals for either men (7 ms
increase; 95% CI: 4.5 to 17 ms, n ¼ 107; p ¼ 0.167) or
women (1.5 ms decrease; 95% CI: 9.3 to 4.3 ms;
FIGURE 2 Results of the Computational Model of Ventricular Epicardial Myocytes
Wildtype channel
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The APD prolongation (measured as APD70) for each case are 9 ms and 50 ms, simulating
1 mM lansoprazole þ 100 mM ceftriaxone and 10 mM lansoprazole þ 100 mM ceftriaxone,
respectively. Brieﬂy, the model was run for a ventricular action potential paced at 1 Hz with
baseline conditions (black) and 10% or 55% block of peak hERG current (brown and red
respectively). APD70 ¼ action potential duration at 70% of repolarization; other
abbreviations as in Central Illustration.
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changes in QTc interval when further stratifying by
race. See Figure 1C for complete results.
We performed sample-size and effect-size ana-
lyses, which demonstrated that, with 100 patients
prescribed either combination, we would be able to
detect a 10 ms QT interval prolongation with 80%
power; with 1,000 patients, the same effect size could
be detected with 100% power (Online Figure 2).
A total of 603 patients taking ceftriaxone and
lansoprazole had ECGs both before and after they
started combination treatment. To control for base-
line confounders, we performed a paired analysis
comparing each of these patient’s highest QTc in-
terval from ECGs performed up to 36 days before and
after exposure to ceftriaxone and lansoprazole. We
stratiﬁed the analysis by both sex and race. We
observed a statistically signiﬁcant increase in QTc
interval for both white men (14.0  4.0 ms increase;
p ¼ 6.56  104) and white women (12.9  3.3 ms
increase; p ¼ 1.03  104). We observed no signiﬁcant
change in QTc interval for patients prescribed our
negative control. See Online Table 3 for complete
results.
IN COMBINATION, CEFTRIAXONE AND LANSOPRAZOLE
BLOCK THE hERG CHANNEL. Using a test of repeated
measures, we found no signiﬁcant effect from ceftri-
axone on the hERG channel (p ¼ 0.096). We found a
signiﬁcant effect from lansoprazole alone (p ¼ 1.63 
104), causing a drop in current to 86.6  16.7% at
10 mM (no effect at 1 or 0.1 mM). In the presence of 1 mM
lansoprazole, ceftriaxone caused a dose-dependent
drop in current (96.8  13.2% of control at 0.1 mM;
and 89.3  13.2% at 100 mM; p ¼ 1.07  104). In the
presence of 10 mM lansoprazole, ceftriaxone caused a
dose-dependent drop in current (63.1  10.9% of
control at 0.1 mM; and 42.4  11.6% at 100 mM;
p < 3.45  105) (Figure 1D, left). For our negative
control, we saw a small block in cefuroxime alone
(94.0  14.8% of control at 100 mM cefuroxime;
p ¼ 5.62  105) but no dose-dependent response of
cefuroxime combined with 1 mM lansoprazole
(p ¼ 0.083) (Figure 1D, right).
COMPUTATIONAL MODEL RECAPITULATES CLINICAL
OBSERVATIONS. Using the hERG current blocks
observed in the electrophysiology experiments as
input to the computational model, the APD prolon-
gation (measured as APD70) was 9 ms for the combi-
nation of 1 mM lansoprazole and 100 mM ceftriaxone
and 50 ms for 10 mM lansoprazole and 100 mM ceftri-
axone (Figure 2). For the combination of 1 mM lanso-
prazole and 100 mM cefuroxime, the APD70 was
shortened by 2 ms.NO EVIDENCE OF CLASS EFFECTS BETWEEN
CEPHALOSPORINS AND PPIs. Given our identiﬁca-
tion of a putative drug interaction between a cepha-
losporin antibiotic and a PPI, we systematically
evaluated all combinations of cephalosporins and
PPIs for evidence of a drug interaction in FAERS,
EHR, or both (Figure 3). The combination of ceftriax-
one and lansoprazole in men was the only drug pair
that had evidence in both FAERS and the EHR that
also passed our confounder analysis for concomitant
medications.
DISCUSSION
NEW DATA SOURCES PRESENT NEW AVENUES FOR
DISCOVERY. Data science and large clinical databases
present new opportunities to discover adverse drug
effects and drug-drug interactions. This is especially
true in situations where traditional methods are
impractical or unfeasible, as is often the case for DDIs.
There are many advantages to taking a retrospective
approach for detecting DDIs. The analyses are rela-
tively rapid and inexpensive to perform, and because
they are in situ, they focus on drug combinations that
are actually used together in clinical practice. In
particular, our use of latent signal detection to mine
for DDIs using side-effect proﬁle models allowed us
to circumvent many of the limitations inherent in
FIGURE 3 Analysis of Class Effects Between Cephalosporins and PPIs
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We analyzed each cephalosporin and PPI pair for evidence of an interaction in FAERS (solid
box ¼ drug pair matches side effect proﬁle), EHR (red ¼ patients on combination have
signiﬁcantly prolonged QT intervals compared with those on either drug alone; blue ¼ no
signiﬁcant change between cases and controls; open ¼ no patients on the drug pair in the
EHR), and that the change seen in the EHR was not due to concomitant medications
(red star). We stratiﬁed the analysis between men and women. Only ceftriaxone and
lansoprazole in men passed each of these criteria. Abbreviations as in Central Illustration.
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1762conventional data mining approaches that rely solely
on direct evidence between drug pairs and side
effects (13,14). However, there are many disadvan-
tages as well. Retrospective analysis, and data mining
in particular, are notorious for their potential biases
and high false discovery rates. There are simply too
many potentially confounding variables to make
strong statements about causal relationships.
Here, we present a novel strategy that couples
observational data mining with laboratory experi-
ments to identify QT-DDIs (Central Illustration). Our
observational analysis establishes the presence of
a clinically signiﬁcant association between
co-medication and a prolonged QT interval. There
are many hypotheses that may explain such an
association. For example, a patient prescribed the
putative interacting drugs may also be prescribed aknown QT-prolonging agent. In fact, this is what we
observed. Of 34 drug combinations that were asso-
ciated with increased QT intervals, 26 could be
dismissed as likely confounded by a known agent.
Alternatively, it may be that there is a real drug
interaction, in the pharmacological sense. The most
common physiological explanation would be hERG
block; therefore, we tested this hypothesis for
our top prediction (ceftriaxone/lansoprazole) by
using patch-clamp electrophysiology. This atypical
path, going from the clinic into the laboratory,
has great potential to increase the efﬁciency of
DDI discovery.
CRITICAL EVALUATION OF DATA MINING USING
LABORATORY EXPERIMENTS. We combined data
from FAERS with our local EHR to ﬁnd evidence of
QT-prolonging drug interactions. Either data source
alone provides only weak evidence of a potential DDI
producing thousands of equivalent hypotheses. By
integrating these data, we increased power and
focused the analysis on only the strongest candidates.
Most importantly, we followed up on these DDI
hypotheses by using laboratory experiments to iden-
tify a possible mechanism.
AN INTERACTION BETWEEN CEFTRIAXONE AND
LANSOPRAZOLE IS UNEXPECTED. Our top candi-
date, ceftriaxone and lansoprazole, would not have
been suspected using current surveillance methods.
In the clinical records, we found that co-medication
of these 2 common drugs is associated with signiﬁ-
cantly prolonged QTc intervals. This increase was
highest for white men and black women, in whom we
observed an average increase of 12 ms. It is important
to note that, if this effect size was observed for a
single drug, it would be well above the threshold for
regulatory concern during the approval stage (3). In
the laboratory, we found that, in combination, lan-
soprazole and ceftriaxone block the hERG channel up
to 57.6%, corresponding to an APD70 increase of 50
ms. At these higher lansoprazole concentrations, it is
likely that, if treated as a single entity, the combina-
tion would not have received regulatory approval.
STUDY LIMITATIONS. We discovered that ceftriaxone
and lansoprazole were signiﬁcantly associated with
prolonged QT intervals using clinical data. Our labo-
ratory analysis suggests that this effect may be
mediated through the hERG potassium channel, the
most common mechanism by which drugs prolong
the QT interval. However, the molecular explanation
is not clear. Possibilities include a chemical interac-
tion between the 2 compounds, cooperative binding
to the channel, or an indirect mechanism through
proteins that function with hERG. Furthermore, we
CENTRAL ILLUSTRATION Ceftriaxone and Lansoprazole Are Associated With Acquired LQTS
Lorberbaum, T. et al. J Am Coll Cardiol. 2016;68(16):1756–64.
We combined mining of adverse event reports, corroboration in electronic health records, and experimental validation using single-cell patch clamp to discover and
validate a QT-DDI between ceftriaxone and lansoprazole. We used a data-driven proﬁle of side effects that are predictive of LQTS to prioritize drug pairs in FAERS. We
corroborated these ﬁndings in the electronic health records by comparing the QTc intervals of patients administered the prioritized drug pair to patients exposed to
either drug alone. We then validated our top prediction (ceftriaxone/lansoprazole) by measuring the dose-dependent changes in hERG channel current using patch-
clamp electrophysiology. AFib ¼ atrial ﬁbrillation; FAERS ¼ FDA Adverse Event Reporting System; hERG ¼ human Ether-à-go-go-Related Gene; LQTS ¼ long QT
syndrome; QT-DDI ¼ QT-prolonging drug-drug interaction; VTach ¼ ventricular tachycardia.
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1763found signiﬁcantly different effects when our anal-
ysis was stratiﬁed by race and ethnicity. White men
and women appear to be sensitive to the interaction,
whereas black men experience only an intermediate
change, and women identifying as “other, including
Hispanic” experience no detectable effect. This is
consistent with the large amount of ethnic heteroge-
neity in cardiac potassium channels (24,25) and may
guide a structural analysis of the interaction.
PRIOR EVIDENCE OF RELATED ADVERSE EVENTS.
Lansoprazole is a commonly used PPI that is avail-
able over-the-counter. In retrospective analyses,
PPIs were associated with a slightly increased risk of
myocardial infarction (26). Additionally, there have
been a large number of deaths reported to the FDA for
patients taking this class of drugs, although this as-
sociation is not statistically signiﬁcant. Our discovery
of a drug interaction with a PPI may explain theseobservations, although this requires follow-up study.
Notably, evaluation of cefuroxime and lansoprazole,
a pair predicted not to interact from the FAERS
reporting frequencies, suggests that our pipeline is
capable of distinguishing between safe and unsafe
pairs, even within the same drug class.
CONCLUSIONS
We present evidence of a novel QT-DDI between lan-
soprazole and ceftriaxone. This interaction was
discovered by using a combination of data mining and
laboratory experiments. Our clinical data suggest that
patients taking this pair of interacting drugs are more
likely to have acquired LQTS, and the experimental
study suggests that this effect may be mediated by
blocking the hERG channel, the most common mech-
anism of acquired LQTS. This interaction appears to be
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE:
Data science methodologies may accelerate evalua-
tion of the safety of drug combinations. Data from
large numbers of patients and ECGs in electronic
health records can corroborate clinical event reports
of adverse drug interactions and, for those involving
QT-interval prolongation, laboratory methods can
then be used to elucidate the electrophysiological
mechanisms involved.
TRANSLATIONAL OUTLOOK: Further work is
needed to systematically extend this paradigm to
evaluate the safety of commonly used drug combi-
nations in other cardiovascular domains.
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1764speciﬁc to ceftriaxone and does not extend to
other cephalosporin antibiotics in combination with
lansoprazole. Follow-up studies are required to
conﬁrm our ﬁndings and should include evaluation of
the mechanism of the interaction at the hERG channel,
the effect of ceftriaxone and lansoprazole on other ion
channels, and investigation of these drugs in combi-
nation with other hERG blockers.
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